Priser
Platform
Blog
Om os
Download
Bio View
Bio View
Tel Aviv Stock Exchange
0

Om

Bio View Ltd. is a company specializing in the development, manufacture, and marketing of advanced imaging and analysis solutions for cancer detection and monitoring. Their primary products include automated cell-imaging systems that assist pathologists and laboratory scientists in accurately diagnosing and tailoring patient treatment plans. Bio View Ltd.'s innovative technology supports various medical areas, including hematology, cytology, and pathology, significantly aiding in identifying cancerous cells in a range of specimens. The company's systems are widely used in hospital labs, research facilities, and pharmaceuticals, providing critical support in the management and study of diseases. With its headquarters in Israel, Bio View Ltd. plays a crucial role in the life sciences sector, contributing to advancements in personalized medicine by enhancing the precision and efficiency of diagnostic processes. Its products are integral in the quest for better cancer management, aligning with global health objectives of early diagnosis and treatment of oncological conditions.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I BIO VIEW MED ENDAVU: Køb Bio View ($BIOV) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Bio View, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

TickerBIOV
Land
Israel
Antal medarbejdere29
Hjemmesidebioview.com
SektorSundhed
IndustriMedicinsk udstyr

Udbytter

0ILS
'17
Ex-udbytte-dato22. mar. 2017
Udbytteafkast0%